BioPharm News

Oct 24, 2017
By BioPharm International Editors
Girish Malhorta, CPhI expert and president of EPCOT International, discussed world revenues for pharmaceuticals and how companies may improve cost and availability of drugs in CPhI’s 2017 Annual Report.
Oct 23, 2017
By BioPharm International Editors
The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.
Oct 23, 2017
By BioPharm International Editors
The clinical-stage biopharmaceutical company has announced the opening of a new gene therapy manufacturing facility in Modiin, Israel, which is anticipated to be the production site of the company’s lead cancer drug candidate.
Oct 23, 2017
By BioPharm International Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 23, 2017
By BioPharm International Editors
The company is recalling several injectable products because of possible microbial contamination.
Oct 23, 2017
By BioPharm International Editors
EDQM held a symposium on microbiology to gather industry feedback on alternative testing methods for microbiological control and sterilization processes.
Oct 20, 2017
By BioPharm International Editors
The companies will embark on a joint antimicrobial research project, with the intent to discover antibiotic combinations that target resistance.
Oct 20, 2017
By BioPharm International Editors
The company has announced that it has acquired a new bioanalysis and biomarkers services facility in Laval, Montreal, Canada to support preclinical and clinical programs.
Oct 20, 2017
By BioPharm International Editors
SCHOTT began production of glass ampoules, vials, and cartridges at a new facility at the SCHOTT Xinkang headquarters in Zhejiang, China.
Oct 20, 2017
By BioPharm International Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
native1_300x100
lorem ipsum